论文部分内容阅读
目的观察CXCL16和氧化低密度脂蛋白(ox-LDL)在阿霉素肾病小鼠血、尿及肾组织中的变化,探讨其与阿霉素肾病发生发展的关系。方法将50只雄性Balb/c小鼠分为模型组与对照组。模型组予以一次性尾静脉注射阿霉素10.5 mg/kg建模,对照组经尾静脉注射同样剂量的生理盐水。分别于实验0、1、3、5、7周末测24 h尿蛋白定量,全自动生化分析仪检测血清白蛋白、胆固醇,双抗体夹心ELISA方法检测血清CXCL16、ox-LDL及尿液CXCL16,免疫组织化学SABC法检测肾组织CXCL16及ox-LDL表达,PAS染色观察肾脏组织学改变。结果与对照组相比,模型组小鼠1周末出现血清白蛋白降低(P<0.05),血清胆固醇及24 h尿蛋白定量升高(P<0.05或P<0.01),且持续至实验结束;模型组小鼠血尿CXCL16及血清ox-LDL水平明显增高(P<0.01),且随着时间延长逐渐增高;模型组肾小球CXCL16、ox-LDL表达较对照组增强(P<0.01),且随着时间延长表达逐渐增强。结论 CXCL16和ox-LDL均参与了阿霉素肾病的发生发展,且与疾病的严重程度有关。血清和尿液CXCL16水平可作为评价其肾组织病理损伤严重程度的无创性指标。
Objective To investigate the changes of CXCL16 and ox-LDL in the blood, urine and kidney of adriamycin-induced nephropathy mice and to explore its relationship with the occurrence and development of adriamycin nephropathy. Methods Fifty male Balb / c mice were divided into model group and control group. One-time tail vein injection of doxorubicin 10.5 mg / kg was modeled in the model group, while the control group was injected with the same dose of saline through tail vein. Serum albumin, cholesterol and double antibody sandwich ELISA method were used to detect serum CXCL16, ox-LDL and urine CXCL16 at the end of 0, 1, 3, 5 and 7 weeks respectively. Immunohistochemistry The histochemical SABC method was used to detect the expression of CXCL16 and ox-LDL in renal tissue. The renal histological changes were observed by PAS staining. Results Compared with the control group, the mice in the model group showed a decrease in serum albumin (P <0.05) and a rise in serum cholesterol and 24 h urine protein (P <0.05 or P <0.01) at the end of the experiment, The levels of CXCL16 and ox-LDL in model group were significantly higher than those in control group (P <0.01), and gradually increased with time. The expressions of CXCL16 and ox-LDL in glomerulus in model group were significantly higher than those in control group (P <0.01) With time extended expression gradually increased. Conclusion Both CXCL16 and ox-LDL are involved in the development of adriamycin nephropathy, and are related to the severity of the disease. Serum and urine CXCL16 levels can be used as a noninvasive index to evaluate the severity of renal pathological damage.